Hemophilia A

Study of Biostate® in Children With Hemophilia A

NCT01229007 | PHASE 3 | INTERVENTIONAL

The objective of this study is to assess the efficacy and safety of a Von Willebrand Factor/Factor VIII (VWF/FVIII), Biostate, and to investigate the pharmacokinetics of Biostate in children with haemophilia A.

8 Sites

35 Participants

Recruiting

12 Months to 12 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Study site

Gomel,Belarus,246040

Study site

Minsk,Belarus,223040

Study Site

Tbilisi,Georgia,0179

Study Site

Guatemala,Guatemala,01010

Study Site

Beirut,Lebanon

Study site

Monterrey,Mexico,64000

Study Site

Dnipropetrovsk,Ukraine

Study Site

Lviv,Ukraine

Study Eligibility Criteria

Inclusion Criteria

* Male subjects between 0 and \<12 years of age.
* Diagnosed with severe haemophilia A (FVIII:C \<1%), and pre-treated for a minimum of 20 to 50 exposure days.
* Have evidence of vaccination against hepatitis A and B (or presence of antibodies against hepatitis A and B due to either a previous infection or prior immunisation), as documented in the medical notes at enrolment.
* The subject and/or legal guardian understand(s) the nature of the study and has/have given written informed consent to participate in the study and is/are willing to comply with the protocol.

Exclusion Criteria

* For all subjects at Day 1: Are actively bleeding.
* Have received an infusion of any FVIII product, cryoprecipitate, whole blood, plasma or desmopressin acetate in the 4 days prior to their dosing within the PK component.
* Have a known history of, or who are suspected of having FVIII inhibitors.
* Have received aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) within 7 days of administration of the IMP.
* Have an impaired liver function ie, bilirubin \>1.5 x upper limit of normal (ULN) and/or aspartate/alanine aminotransferase (AST/ALT) \>2.5 x ULN (referring to limits of the laboratory that performs the determination) at Screening.
* Are human immunodeficiency virus \[HIV\]-1/-2 antibody positive with a viral load of \>200/µL.
* Suffer from an acute or chronic medical condition, other than haemophilia A, which may, in the opinion of the Investigator, affect the conduct of the study.
* Suffering from von Willebrand disease (VWD) with von Willebrand factor: ristocetin cofactor (VWF:RCo) level \<50 IU/dL at Screening.
* Have a known or suspected hypersensitivity or previous evidence of severe side effects to a plasma-derived FVIII product or to human albumin.
* Have participated in a clinical study or used an investigational compound in another study (eg, a new chemical entity not registered for clinical use) in the 3 months preceding the first day of IMP administration, or are planning to enter such a study during the study period.
* Unwillingness and/or inability to comply with the study requirements.

Additional Studies

Additional studies can be found at ClinicalTrials.gov